V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Repare Therapeutics Executive Compensation (FY24)

RPTX · Executive and director compensation, fiscal 2023 to 2024

The Repare Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): June 17, 2025
6 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Repare Therapeutics brief$1,500Get the executive brief
131 figures on this page: 127 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
Latest say-on-pay support
=
June 17, 2025
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Lloyd Segal: $4,991,804 → $2,368,837 (52.5% lower)

Frequently asked questions

Answers drawn from the data on this page.
What was Repare Therapeutics' say-on-pay result?
The say-on-pay proposal drew 94.1% support at the meeting held June 17, 2025 for fiscal 2024.
Which companies are in Repare Therapeutics' peer group?
The disclosed peer group names ALX Oncology, Aura Biosciences, Bicycle Therapeutics, Foghorn Therapeutics and IDEAYA Biosciences, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Lloyd Segal
Former President and Chief Executive Officer
◇—◇◇◇—◇◇
Maria Koehler
Former Executive Vice President, Chief Medical Officer
◇—◇◇◇—◇◇
Michael Zinda
Executive Vice President, Chief Scientific Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Lloyd Segal
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇◇—◇◇
Maria Koehler
Former Executive Vice President, Chief Medical Officer
Departed during or after this year
◇◇◇◇◇—◇◇
Michael Zinda
Executive Vice President, Chief Scientific Officer
◇◇◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Maria KoehlerRSU◇◇——
Option◇—◇1/29/2033
Option◇—◇1/17/2032
Option◇—◇2/28/2034
Option◇—◇2/8/2031
RSU◇◇——
Michael ZindaOption◇—◇1/17/2032
RSU◇◇——
Option◇—◇1/29/2033
RSU◇◇——
Option◇—◇2/28/2034
Option◇—◇2/8/2031
Lloyd SegalRSU◇◇——
RSU◇◇——
Option◇—◇1/20/2032
Option◇—◇1/29/2033
Option◇—◇2/28/2034
Option◇—◇2/8/2031
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Steven Stein, M.D
◇—◇———◇
Thomas Civik
Board chair
◇—◇——◇◇
Ann D. Rhoads
◇—◇——◇◇
Carol A. Schafer
◇—◇——◇◇
Susan M. Molineaux, Ph.D
◇—◇——◇◇
David Bonita, M.D
◇—◇———◇
Samarth Kulkarni, Ph.D
◇—◇——◇◇
Briggs Morrison, M.D
◇—◇———◇
Todd Foley
◇————◇◇
Steve Forte served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • ALX Oncology ALXO
  • Aura Biosciences AURA
  • Bicycle Therapeutics BCYC
  • Foghorn Therapeutics FHTX
  • IDEAYA Biosciences IDYA
  • Inhibrx INBX
  • Iteos Therapeutics ITOS
  • Keros Therapeutics KROS
  • Mersana Therapeutics MRSN
  • Monte Rosa Therapeutics GLUE
  • PMV Pharmaceuticals PMVP
  • Poseida Therapeutics PSTX
  • RAPT Therapeutics RAPT
  • Replimune Group REPL
  • Stoke Therapeutics STOK
  • Tango Therapeutics TNGX
  • Y-mAbs Therapeutics YMAB
  • Zentalis Pharmaceuticals ZNTL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024June 17, 2025=◇◇◇
2023June 17, 2024=◇◇◇
2022June 8, 2023=◇◇◇
2021May 13, 2022=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Repare Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Repare Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Repare Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Repare Therapeutics' disclosed peer group is defensible, who names Repare Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
131 figures on this page: 127 cited to the filing that reported them, 4 calculated from figures it prints.
127 cited to the filing
4 calculated from the filing

Documents cited

  1. 0001193125-25-142045
  2. 0001193125-25-103764
    Director Compensation Table · NON-EMPLOYEE DIRECTOR COMPENSATION · Outstanding Equity Awards as of December 31, 2024 · Outstanding Equity Awards at Fiscal Year End · and 1 more section
  3. 0001193125-24-162595
  4. 0001193125-24-117976
    Summary Compensation Table
  5. 0001193125-23-164566
  6. 0001193125-22-150978
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Repare Therapeutics executive compensation, FY2023–FY2024.” https://intel.velarion.ai/comp/RPTX (accessed 2026).
Short form: data: Velarion

The Repare Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Repare Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Repare Therapeutics discloses

The companies named in RPTX's own disclosed peer group.

ALX OncologyAura BiosciencesBicycle TherapeuticsFoghorn TherapeuticsIDEAYA BiosciencesInhibrxIteos TherapeuticsKeros TherapeuticsMersana TherapeuticsMonte Rosa TherapeuticsPoseida TherapeuticsRAPT TherapeuticsReplimune GroupStoke TherapeuticsTango TherapeuticsY-mAbs TherapeuticsZentalis Pharmaceuticals

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy